Company Profile
Xenetic Stock Price, News & Analysis
- Ticker:
- XBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.85 USD (-3.72%)
Close
Last updated: August 6, 2026
7.74M USD
Market cap
Why the stock is moving
The latest monitored company update is “Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform.” The corresponding closing-price reaction is not yet available.
Company overview
DNase Oncology Platform
Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.
Tumor Microenvironment Strategy
The platform targets neutrophil extracellular traps and other DNA-rich components of the tumor microenvironment that may promote metastasis and suppress immune activity.
Translational Development
Xenetic is advancing investigator-sponsored research, biomarker work, manufacturing development, and clinical planning to establish the foundation for future oncology studies.
Future catalysts
For Xenetic, the near-term story still runs through its latest development priorities. Recent commentary puts the focus on Generated robust translational data supporting the DNase I platform across multiple oncology settings Completed process improvement and analytical development activities.... That leaves the stock tied to whether the next milestone lands on schedule.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xenetic (XBIO)?
Xenetic (XBIO) most recently closed at 2.85 USD, a -3.72% move versus the previous session.
What is the market cap of Xenetic (XBIO)?
Xenetic currently has a market capitalization of 7.74M USD on BioPharmSignal.
What does Xenetic do?
DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance. Tumor Microenvironment Strategy The platform targets neutrophil extracellular traps and other DNA-rich components of the tumor microenvironment that may promote metastasis...
On which exchange is XBIO stock listed?
Xenetic (XBIO) is associated with NASDAQ, United States, Biopharma.
What is DNase?
Recent commentary puts the focus on Generated robust translational data supporting the DNase I platform across multiple oncology settings Completed process improvement and analytical development activities....
Which conditions is Xenetic targeting with DNase?
Xenetic is associated with oncology based on its company overview and current catalyst commentary.
How does Xenetic describe recent progress with DNase?
Recent commentary puts the focus on Generated robust translational data supporting the DNase I platform across multiple oncology settings Completed process improvement and analytical development activities....
What is Oncology?
DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.